DAVID CHAPPELL: Open Payments
NPI 1598732463 · PETALUMA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,244 in 51 payments from 14 companies in 2025. Trend: 2023 $1,357 · 2024 $1,791 · 2025 $1,244
Food & beverage: $1,244
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 10 | $242 |
| Novo Nordisk Inc | 10 | $225 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $148 |
| Xeris Pharmaceuticals, Inc. | 6 | $138 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $125 |
| Amgen Inc. | 4 | $117 |
| ABBVIE INC. | 3 | $82 |
| Ascendis Pharma Endocrinology Inc | 1 | $28 |
| Dexcom, Inc. | 1 | $27 |
| Novartis Pharmaceuticals Corporation | 1 | $27 |
Products named: JARDIANCE, RECORLEV, Kerendia, MOUNJARO, Ozempic, TEPEZZA, QULIPTA, Wegovy.
Industry payments across CA — which companies pay providers there.
